CHMP recommends Innovent's Zybrivo sintilimab for first-line non-squamous lung cancer in Europe

The EMA's CHMP has recommended Innovent's Zybrivo, containing sintilimab, for first-line treatment of eligible patients with non-squamous non-small cell lung cancer, advancing the immunotherapy towards a potential European marketing authorisation.
Innovent announced that the European Medicines Agency's Committee for Medicinal Products for Human Use adopted a positive opinion on 12 November 2026 recommending Zybrivo (sintilimab) in combination with chemotherapy for first-line treatment of eligible adults with non-squamous non-small cell lung cancer without EGFR or ALK genomic aberrations, regardless of PD-L1 expression.
The recommendation is supported by clinical evidence showing improved progression-free survival compared with chemotherapy alone and represents an important European regulatory milestone for the PD-1-targeting immunotherapy, but the European Commission must still issue its final marketing authorisation decision before the recommendation becomes an EU approval.
Field | Content |
Article Type | Approvals |
Company | Innovent |
Product Brand Name | Zybrivo |
Active Ingredient | Sintilimab |
Drug Classification | Immune checkpoint inhibitor |
Molecular Target | PD-1 |
Regulatory Authority | European Medicines Agency |
Regulatory Committee | Committee for Medicinal Products for Human Use |
Regulatory Committee Abbreviation | CHMP |
Opinion Date | 12 November 2026 |
Regulatory Outcome | Positive CHMP opinion |
Regulatory Recommendation | Marketing authorisation recommended |
Final European Commission Approval | Not yet granted according to supplied summary |
Regulatory Market | European Union |
Therapeutic Area | Oncology |
Cancer Type | Non-small cell lung cancer |
Histological Subtype | Non-squamous |
Treatment Line | First line |
Proposed Treatment Regimen | Sintilimab in combination with chemotherapy |
Proposed Patient Population | Eligible adults with non-squamous non-small cell lung cancer without EGFR or ALK genomic aberrations |
EGFR Status Requirement | No EGFR genomic aberrations |
ALK Status Requirement | No ALK genomic aberrations |
PD-L1 Eligibility | Irrespective of PD-L1 expression |
Supporting Clinical Evidence | Clinical trial evidence of improved progression-free survival |
Progression-Free Survival Finding | Improvement versus chemotherapy alone |
Overall Survival Results | Not specified in supplied summary |
Commercial Launch Status | Not yet authorised for launch on the basis of this CHMP opinion |
What Happened | The CHMP recommended European marketing authorisation for Zybrivo in a specified first-line lung cancer setting. |
Why It Matters | The recommendation moves another immunotherapy option closer to potential availability for eligible European lung cancer patients. |
Clinical Significance | Supporting evidence demonstrated improved progression-free survival when sintilimab was combined with chemotherapy. |
Regulatory Significance | Represents a positive scientific opinion preceding a potential European Commission marketing authorisation. |
Regulatory Clarification | A positive CHMP opinion is not a final European Commission approval. |
Key Takeaway | Zybrivo has received a positive CHMP recommendation for first-line non-squamous lung cancer, with the final EU authorisation decision still pending. |
What to Watch | European Commission decision, final authorised product information, reimbursement assessments and European commercialisation plans. |
Primary Source | European Medicines Agency |
Primary Source URL | https://www.ema.europa.eu/en/medicines/human/EPAR/zybrivo |
Submitted Source | Innovent announcement |
Submitted Source URL | https://www.prnewswire.com/news-releases/innovent-announces-positive-chmp-opinion-recommending-zybrivo-sintilimab-for-first-line-treatment-of-non-squamous-non-small-cell-lung-cancer-302939658.html |
Relevant Date | 12 November 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com


Kommentare